Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19

NCT04497948 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT04497948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04497948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19
Lead sponsor
Acerta Pharma BV
Phase
Phase 1
Overall status
Terminated
Start date
September 21, 2020
Completion date
November 18, 2020
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19